Table 2

Response rates

VD, %vtD, %P*
After 2 cycles†    
    CR (negative immunofixation) 6 4 .52 
        ≥ nCR 16 16 1 
        ≥ VGPR 21 24 .60 
        ≥ PR 77 90 .01 
After 4 cycles‡    
    CR (negative immunofixation) 12 13 .74 
        ≥ nCR 22 31 .15 
        ≥ VGPR 36 49 .05 
        ≥ PR 81 88 .19 
After 1 course of melphalan 200 and ASCT§    
    CR (negative immunofixation) 31 29 .77 
        ≥ nCR 52 61 .20 
        ≥ VGPR 58 74 .02 
        ≥ PR 86 89 .54 
VD, %vtD, %P*
After 2 cycles†    
    CR (negative immunofixation) 6 4 .52 
        ≥ nCR 16 16 1 
        ≥ VGPR 21 24 .60 
        ≥ PR 77 90 .01 
After 4 cycles‡    
    CR (negative immunofixation) 12 13 .74 
        ≥ nCR 22 31 .15 
        ≥ VGPR 36 49 .05 
        ≥ PR 81 88 .19 
After 1 course of melphalan 200 and ASCT§    
    CR (negative immunofixation) 31 29 .77 
        ≥ nCR 52 61 .20 
        ≥ VGPR 58 74 .02 
        ≥ PR 86 89 .54 
*

χ2 test.

†

Five and 3 patients had local and not centralized evaluations in the VD and vtD arms, respectively.

‡

Two and 2 patients had local and not centralized evaluations in the VD and vtD arms, respectively.

§

Eight and 2 patients had local and not centralized evaluations in the VD and vtD arms, respectively.

View Large